How e-Patients are Learning and Sharing Information about Pre-Approval Therapies

67 %
33 %
Information about How e-Patients are Learning and Sharing Information about Pre-Approval...
Health & Medicine

Published on February 13, 2014

Author: TeamInspire

Source: slideshare.net

Description

Presentation by Inspire CEO Brian Loew to the Patient-Centered Technologies for Post-Marketing and Real World Data conference

How e-Patients are Learning and Sharing Information about Pre-Approval Therapies brian@inspire.com @teaminspire Patient-Centered Technologies for Post-Marketing and Real World Data Research February 6, 2014 Brian Loew, CEO, Inspire www.Inspire.com Thursday, February 13, 14

Patients are increasingly seeking and sharing information online about drugs before FDA approval Examples from our ovarian, lung, prostate and advanced breast cancer groups: • “About temsirolimus: Right after my cancer returned 3 months after the completion of the taxol-platinum regimen, my doctor sent me to the U of Penn to enroll in a study...I was delighted to find that it was reducing the size of my tumor, though it never completely eliminated it.” • “If the resistance to Tarceva is due to the T790M mutation, there are two promising drugs in clinical trials right now. One is from Clovis called CO-1686, the other from AstraZeneca called AZD9291.” • “Nivolumab 3mg/kg every 2 weeks HAS worked for me one tumor so small no longer measurable. I knew it was working as I just felt better almost immediately.” Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

More sharing–driven entirely by engaged, insightful patients: • “The phase 3 trial that is just starting is using Mekinist, which is FDA approved for Melanoma. Your doc should make a case to your insurance to cover this drug for your treatment and start you on it outside of the trial.” • “There is a drug in prostate cancer that targets CLTA-4 in clinical trials.” • “When deciding between continuing on anti-PD1 trial or switching to chemotherapy, I think you need to consider at least two things: 1) What is the response rate for the chemotherapy you'd receive as 3rd(?) line treatment? 2) Many of the immunotherapy clinical trials have an exclusion if you've had any prior immunotherapy treatment.” • “I would try (bazedoxifene) in a heartbeat if current treatment tamoxifen fails and I could get it.” • “My onc is at the Cleveland Clinic and just offered (Torisel) to me. He gave me the choice of avastin and three other drugs. He thought that temsirolimus would be the best choice along with avastin.” Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Discovery Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Discovery When someone recently started a discussion about privacy issues, I got a little concerned that too much privacy might have prevented me from finding what has been the most useful, supportive group for me. Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

The “Tarceva Diva,” and her Divas & Dudes • In Inspire’s Lung Cancer Survivors Support Community, one now-deceased member, “MarieZee100,” began a discussion topic--on her own--to connect people who are or were on Tarceva • In just her “Tarceva Divas” discussion strings alone, apx. 8,000 posts by members, over apx. 30 months • Discussed not just Tarceva itself, but new drugs and combination therapies • Strength of self-organized “sub-community”--MarieZee100 has died of lung cancer, but another member picked up the “Tarceva Diva” mantle, and the discussion topic continues stronger than ever. Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

A rare disease patient’s story Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Discovery, as a community finds itself Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Rare disease e-patients’ call to action Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Takeaways: Patients are engaged in seeking and sharing detailed information about pre-approval therapies. Many patients want to contribute to research. Technology matters a great deal. Technology doesn’t matter at all. Brian Loew, brian@inspire.com, @teaminspire Thursday, February 13, 14 www.Inspire.com

Add a comment

Related presentations

Related pages

How e-Patients are Learning and Sharing Information about ...

1.How e-Patients are Learning and Sharing Information about Pre-Approval Therapies brian@inspire.com @teaminspirePatient-Centered Technologies for Post ...
Read more

Patient-Centered Technologies for Post-Marketing and Real ...

Patient-Centered Technologies for Post-Marketing and Real World ... 10:40 How e-Patients are Learning and Sharing Information about Pre-Approval Therapies.
Read more

Inspire News - March/April 2014 - Inspire

Inspire works with trusted health partners to build safe and ... How e-Patients are Learning and Sharing Information about Pre-Approval Therapies, ...
Read more

1000+ images about About Inspire on Pinterest | Pulmonary ...

... patients use NF-related social media for information gathering more than emotional support http ... About Inspire Partners Including Inspire ...
Read more

News & publications - Inspire

How e-Patients are Learning and Sharing Information about Pre-Approval Therapies Presentation by Inspire CEO ... e-Patients.net by member of Inspire's ...
Read more

Personalized Oncology – Fulfilling the Promise for Today’s ...

Plenary Keynote Wednesday, February ... patients to the best available therapies for their tumors, and learning as much as ... Sharing: e-Trials and e ...
Read more

Applebaum preapproval - Documents

Applebaum preapproval; Applebaum preapproval Oct 22, 2014 Documents. of 1
Read more

Prequalification and Preapproval - Documents

Prequalification and Preapproval. by brocklobster. on Feb 03, 2015. Report Category: Documents
Read more